FDA approves topical solution for low testosterone
The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The treatment is the first testosterone topical solution approved for application via an armpit applicator, according to manufacturers Eli Lilly and Co. and Acrux.
A phase III multicenter, open-label, 120-day clinical study demonstrated that 84% of men who completed the study achieved average serum testosterone concentration within the normal range of 300 to 1,050 ng/dL. Additionally, after 120 days of treatment, 75% of responding patients finished the study on the recommended starting dose of 60 mg.
The most common adverse reactions (incidence greater than 4%) in the study were skin application site reactions, increased red blood cell count, headache, diarrhea, vomiting, and an increase in PSA.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
